Viral hepatitis includes five distinct disease entities, which are caused by at least five different viruses. Hepatitis A and hepatitis B (infectious and serum hepatitis, respectively) are considered separate diseases and both can be diagnosed by a specific serologic test. Hepatitis C and E comprise a third category, each a distinct type, with Hepatitis C parenterally transmitted, and hepatitis...

Hepatitis D virus causes an aggressive viral hepatitis with a virulent course of progression to cirrhosis and hepatic decompensation. It relies on hepatitis B coinfection for its pathogenesis and propagation. Hepatitis D virus had become the forgotten virus, with reduced public awareness, medical interest, and research support. Recently, there has been a resurgence of awareness and interest in ...

1. Distinguish among viral hepatitis A, B, C, D, and E’s virology, epidemiology, and serological response to infection and clinical manifestation. 2. Design a prophylactic and therapeutic plan identifying the risk factors associated with the transmission of viral hepatitis A, B, C, D, or E in a clinical situation. 3. Develop an appropriate prophylactic regimen for preventing viral hepatitis A, ...

s: Chen D, Nagarkatti P, and Nagarkatti M. (2000) Role of CD44 in Con-A induced Hepatitis. 20 Annual Seminar of Cancer Researchers in Virginia. EVMS, Norfolk, VA. Chen D, Nagarkatti P and Nagarkatti M. (2000) Role of CD44 in Con-A induced Hepatitis. IMMUNOLOGY 2000 AAI/CIS Joint Annual Meeting, Seattle, Washington. Presentations at Meetings: Chen D, Nagarkatti P, and Nagarkatti M. (2000) Role o...

Burden of Viral Hepatitis on Human Health Compared to better-publicized infectious diseases such as HIV or malaria, viral hepatitis is often referred to as a silent killer. • Of the five hepatitis viruses (A-E), hepatitis B, C, and D viruses cause chronic liver disease leading to cirrhosis, liver failure and liver cancer. Hepatitis B, C and D viruses, transmitted through blood and body fluids, ...

The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age +/- standard deviation, 36.8 +/- 12.8 years) with chronic hepatitis D who were treated with IFN-alpha2b (10 million U, three tim...